Fagron Compounding Services, LLC

Fagron Compounding Services, LLC, doing business as Fagron Sterile Services, manufactures and delivers sterile compounded pharmaceuticals and pharmacy supplies to federal healthcare agencies as a prime contractor across 19 recent awards totaling $2.9 million in combined potential value. A foreign-owned, for-profit organization headquartered in Wichita, Kansas, Fagron competes exclusively under small-business set-asides on a subset of its prime work and full-and-open on the remainder, with total small business designations applied to its primary IDIQ vehicle and several blanket purchase agreements. The vendor is classified under NAICS 325412 (Pharmaceutical Preparation Manufacturing) and PSC 6505-P (Drugs and Biologicals).

Fagron's customer base spans five federal healthcare agencies with near-perfect concentration in the Defense Health Agency. The Defense Health Agency accounts for 12 of 19 awards (63% of award count) and $2.4 million of the $2.9 million combined potential value (83%), reflecting Fagron's role as a sole-source supplier of compounded pharmaceuticals to Brooke Army Medical Center at Joint Base San Antonio Fort Sam Houston, Texas. The Department of Health and Human Services Indian Health Service accounts for three awards ($419 thousand) supplying the Gallup Indian Medical Center, followed by the Department of Veterans Affairs Veterans Integrated Service Network 22 ($66 thousand) and Veterans Integrated Service Network 1 ($14 thousand), with minimal exposure to the Department of the Army Medical Command.

Fagron holds a single-award Indefinite Delivery, Indefinite Quantity contract with the U.S. Army Medical Command (W81K0024D0003), valued at $1.78 million through September 30, 2029, designated as a total small business set-aside. Twelve delivery orders under this IDIQ carry $751 thousand in combined potential value, with the Defense Health Agency issuing orders between December 2024 and October 2026 for compounded pharmaceutical products including phenylephrine, fentanyl, rocuronium, succinylcholine, and hydromorphone. Fagron also holds blanket purchase agreements with the Indian Health Service for sterile compounded pharmaceuticals to Gallup Indian Medical Center (ceiling $163 thousand, completion April 2028) and previous purchase orders from the Department of Veterans Affairs. Recent representative work includes a $356,929 delivery order from the Defense Health Agency awarded October 1, 2026, for compounded pharmaceuticals at Brooke Army Medical Center (completion September 30, 2030), a $163,125 blanket purchase agreement with the Indian Health Service awarded April 7, 2026, and a $66,178 firm-fixed-price purchase order from the VA Long Beach Healthcare System for sterile solutions awarded December 7, 2023.

Activity has grown substantially — one award per year in 2022 and 2023 to five in 2024 and nine in 2025 — though recent momentum has moderated with only two awards in 2026 year-to-date. One award ($163 thousand to the Indian Health Service) reaches ultimate completion inside the next twenty-four months, presenting limited near-term recompete exposure relative to the vendor's current IDIQ ceiling through 2029. Fagron operates exclusively as a prime contractor with no subcontractor footprint in the source data, and the vendor does not hold positions on government-wide acquisition contracts or agency-wide IDIQs beyond its single-award IDIQ with Army Medical Command.